Crystal Structure of Human Cytochrome P450 2D6*
暂无分享,去创建一个
Frank E. Blaney | Sandeep Modi | F. Blaney | A. Bridges | P. Rowland | S. Modi | D. Eggleston | M. Smyth | Joanna J Jones | Vaughan R. Leydon | A. Oxbrow | C. Lewis | M. Tennant | R. Chenery | Drake S. Eggleston | Paul Rowland | Martin G. Smyth | Jo J. Jones | Amanda K. Oxbrow | Ceri J. Lewis | Mike G. Tennant | Richard J. Chenery | Angela M. Bridges | Joanna J. Jones
[1] D. Nebert,et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.
[2] G. Tucker,et al. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. , 1996, The Biochemical journal.
[3] Francesca Fanelli,et al. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..
[4] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[5] G. Tucker,et al. Functional analysis of CYP2D6.31 variant: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution , 2005, Proteins.
[6] H. Barnes,et al. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[7] Gordon C K Roberts,et al. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. , 2004, The Biochemical journal.
[8] N. Vermeulen,et al. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.
[9] Jose Cosme,et al. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.
[10] Nico P E Vermeulen,et al. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.
[11] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[12] M H Tarbit,et al. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[13] J Deisenhofer,et al. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.
[14] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[15] E. Szczesna-Skorupa,et al. Deletion of a conserved tetrapeptide, PPGP, in P450 2C2 results in loss of enzymatic activity without a change in its cellular location. , 1993, Archives of biochemistry and biophysics.
[16] N. Vermeulen,et al. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. , 2004, Biochemical pharmacology.
[17] T. Richardson,et al. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. , 1997, Archives of biochemistry and biophysics.
[18] C David Stout,et al. Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.
[19] S. Eddy. Hidden Markov models. , 1996, Current opinion in structural biology.
[20] Nico P. E. Vermeulen,et al. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..
[21] O. Gotoh,et al. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.
[22] Ruben Abagyan,et al. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..
[23] S. Imaoka,et al. Catalytic specificity of CYP2D isoforms in rat and human. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[24] M. Ingelman-Sundberg,et al. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. , 2005, Biochemical pharmacology.
[25] Eric F. Johnson,et al. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.
[26] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.
[27] G N Murshudov,et al. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.
[28] G J Kleywegt,et al. Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.
[29] R. Skoda,et al. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. , 1990, Pharmacology & therapeutics.
[30] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[31] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[32] D E McRee,et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.
[33] Lars Ridder,et al. Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450. , 2004, Organic & biomolecular chemistry.
[34] Rebecca C Wade,et al. Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling? , 2005, EMBO reports.
[35] Michael J. E. Sternberg,et al. Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.
[36] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[37] Gordon C K Roberts,et al. Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6* , 2003, The Journal of Biological Chemistry.
[38] M. S. Kim,et al. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. , 2001, Archives of biochemistry and biophysics.
[39] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.
[40] G. Tucker,et al. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[41] C David Stout,et al. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.
[42] W U Primrose,et al. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.
[43] Y. Zhang,et al. Cumene hydroperoxide-supported demethylation reactions catalyzed by cytochrome P450 2B4 lacking the NH2-terminal sequence. , 1999, Biochemical and biophysical research communications.
[44] J. S. Miles,et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.
[45] Chris de Graaf,et al. Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.
[46] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[47] F Peter Guengerich,et al. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. , 2003, Biochemistry.
[48] H. Barnes,et al. Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli: 2C3 encodes the 6 beta-hydroxylase deficient form of P450 3b. , 1993, Archives of Biochemistry and Biophysics.
[49] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[50] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[51] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[52] F. Guengerich,et al. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.
[53] J. Venhorst,et al. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[54] S. London,et al. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution , 1995, Human Genetics.
[55] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .
[56] M. Lennard. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. , 1990, Pharmacology & toxicology.
[57] D. Lewis. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[58] S A van Acker,et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.
[59] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[60] D. Lewis,et al. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[61] G T Tucker,et al. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. , 2001, The Biochemical journal.
[62] Stewart B Kirton,et al. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6 , 2002, Proteins.
[63] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[64] C. Wolf,et al. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. , 1997, Archives of biochemistry and biophysics.
[65] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[66] G. Kleywegt. Use of non-crystallographic symmetry in protein structure refinement. , 1996, Acta crystallographica. Section D, Biological crystallography.
[67] M. Sutcliffe,et al. Why Is Quinidine an Inhibitor of Cytochrome P450 2D6? , 2005, Journal of Biological Chemistry.
[68] J Berendzen,et al. The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.
[69] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.